Cancer specialist goes for a dual listing
Saturday 03 July 2004
Cyclacel, the Scottish biotech company, yesterday became the latest healthcare group to reveal plans to float on Nasdaq and the London Stock Exchange.
The company, which specialises in pioneering cancer treatments, is planning to offer 16 million shares - about 26 per cent of the business - at an indicative price range of between 152p and 182p. This would give Cyclacel a market capitalisation of £91m.
Spiro Rombotis, the chief executive of Cyclacel, said the company was in a race to get its treatments to the market before larger pharmaceutical rivals. "We have the chance to be first to market in a massively important cancer field after Aventis unexpectedly terminated its development of a similar class of drug," Mr Rombotis said. He expects Cyclacel's lead drug, which treats a rare form of blood cancer, to reach the market as early as 2006.
"We have the opportunity to raise new funds when investors can see daylight in our plans.
"Without capital raising it would have been difficult to continue funding the pipeline and investing in the business," he said.
Mr Rombotis and the rest of the management team hold a 13 per cent stake in the business, which will be worth £14m when the company floats. The rest of the share capital is held by about 40 investors from across the globe. All existing shareholders are holding on to their holdings.
Cyclacel had considered floating in 2003, but was put off by weak equity markets and poor sentiment towards new listings. Its decision to float now follows a trend of biotech companies returning to the market.
Not all have been very successful, however. Ark Therapeutics floated in March, but the shares are trading well below its listing price. Norwood Immunology, the new vehicle for Rolf Stahel, formerly of Shire Pharmaceuticals, halved its valuation to £50m.
- 1 Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
- 2 Nick Kyrgios calls former Olympian Dawn Fraser a 'blatant racist' after she tells Wimbledon star to 'go back where their parents came from'
- 3 World learns of app that shows you who unfriended you on Facebook, app promptly crashes
- 4 Chris Moyles reportedly set to make radio comeback with new breakfast show on XFM
- 5 The Greece debt crisis explained in less than 100 words
Florida man sentenced to two-and-a-half years for having sex on the beach in front of a child
Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
Tube strike July 2015: Is it still on? Everything you need to know about the industrial action
Eiji Tsuburaya: Godzilla co-creator honoured in today's interactive Google Doodle
Florida teacher sentenced to 22 years in prison for sexually abusing three pupils
More Britons believe that multiculturalism makes the country worse - not better, says poll
Osborne to cap family benefits at £23,000 – announced ahead of his post-election Budget
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
Sickness and disability benefits could be reduced by £30 a week as part of £12bn welfare cuts
iJobs Money & Business
£40000 - £95000 per annum: Recruitment Genius: This is an exciting opportunity...
competitive: SThree: Are you passionate about sales?Do you have a keen interes...
£17000 - £30000 per annum: Recruitment Genius: This is an exciting opportunity...
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...